Press Releases

Pfizer Inc. announced two additional Phase 3 bococizumab trials, SPIRE-HR and SPIRE-FH , met their primary endpoint, demonstrating a significant reduction in the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at 12 weeks compared to placebo among...

AstraZeneca announced that the EC has granted marketing authorisation for Zavicefta , a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation. The approval includes intravenous use of Zavicefta for...

Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA has accepted for review the company’s new drug applications (NDAs) for two products for adolescent and adult patients with asthma. The first, fluticasone propionate/salmeterol, is a fixed-dose...

Novo Nordisk announces the EMA marketing approval of the mylife(TM) YpsoPump® insulin pump for use with prefilled pump cartridge NovoRapid®PumpCart®. The approval is a key milestone for the collaboration between Novo Nordisk and Ypsomed and their goal to deliver...

Teva Pharmaceutical Industries Ltd. and Antares Pharma, Inc. announced the launch of the generic equivalent to Imitrex injection, 4 mg and 6 mg single-dose, prefilled syringe autoinjectors, in the U.S. Sumatriptan injection is used to treat acute migraine with...

Teva Pharmaceutical Industries Ltd and Antares Pharma, Inc. announced the launch of the generic equivalent to Imitrex®1 (sumatriptan succinate) injection, 4 mg and 6 mg single-dose, prefilled syringe autoinjectors, in the U.S. Sumatriptan injection is used to treat acute...

Teva Pharmaceutical Industries Ltd announced that the EMA Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for CINQAERO® (reslizumab), a humanized interleukin 5 antagonist monoclonal antibody for add-on therapy in adult...